Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01034566

Proton Beam Radiation Therapy in Treating Patients With Retroperitoneal Sarcoma

Proton Radiotherapy for Retroperitoneal Sarcoma

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Abramson Cancer Center at Penn Medicine · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue in patients with retroperitoneal sarcoma. PURPOSE: This phase I trial is studying the side effects and and best dose of proton beam radiation therapy in treating patients with retroperitoneal sarcoma.

Detailed description

Detailed DescriptionPRIMARY OBJECTIVES: I. To determine the feasibility and toxicity of proton radiotherapy for retroperitoneal sarcomas. II. To determine the maximum safe proton radiotherapy dose for retroperitoneal sarcomas. III. To determine the maximally tolerated dose of proton radiotherapy for patients with potentially resectable retroperitoneal sarcoma. (Pre-operative cohort) IV. To assess acute side effects from irradiation using proton beam therapy and dose/volume constraints that are derived from conventional radiotherapy. (Postoperative cohort) SECONDARY OBJECTIVES: I. To assess the clinical effectiveness of proton radiotherapy for retroperitoneal sarcoma. II. To determine the long-term toxicity of proton radiotherapy to the abdomen and pelvis region. III. To monitor for effects of proton treatment on tumor and normal tissues using radiographic imaging (both cohorts) or ex-vivo analysis of tissue samples (preoperative cohort only).

Conditions

Interventions

TypeNameDescription
RADIATIONProton Beam Radiation Therapy

Timeline

Start date
2009-11-01
Primary completion
2012-11-01
Completion
2013-01-01
First posted
2009-12-17
Last updated
2021-06-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01034566. Inclusion in this directory is not an endorsement.